Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Obesity, Metabolic Syndrome
Interventions
fructose restriction diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH), Orthotopic Heart Transplant, Cardiac Rehabilitation, Pediatric Cardiology, Telehealth, Telerehabilitation
Interventions
Pediatric Cardiac Telerehabilitation, Fitness Tracker Only
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684
Conditions
Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Ambrisentan in Children 8-18yrs

NCT01332331
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan - low dose, Ambrisentan - high dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Conditions
Obesity, Childhood Obesity, Hypertension, Diabetes, Dyslipidemia
Interventions
Families on Track Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, NC, North Carolina
Completed Phase 1 Interventional Results available

Olmesartan Pediatric Pharmacokinetic (PK) Study

NCT00151814
Conditions
Hypertension
Interventions
Olmesartan medoxomil
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
12 Months to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Little Rock, Arkansas • La Jolla, California • Louisville, Kentucky + 2 more
Completed No phase listed Observational Results available

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

NCT01420068
Conditions
Hypertension
Interventions
SPP100
Drug
Lead sponsor
Noden Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Dalton, Georgia + 7 more
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Terminated No phase listed Observational

Pediatric Hypertension Registry (PHREG)

NCT03305562
Conditions
Hypertension, Pediatric Disorder
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 17 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Winston-Salem, North Carolina
Conditions
Hypertension, Essential Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pulmonary Hypertension
Interventions
Ultrasound Doppler
Radiation
Lead sponsor
Echosense Ltd.
Industry
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Palo Alto, California
Conditions
Hypertension
Interventions
Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more
Conditions
Hypertension
Interventions
candsartan cilexetil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
37
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 34 more
Conditions
Hypertension
Interventions
ramipril, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 16 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
39
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 33 more
Terminated Not applicable Interventional

Pediatric Obesity Management Study

NCT05622981
Conditions
Obesity, Childhood, Behavior, Eating
Interventions
Age-specific educational materials and monitoring
Behavioral
Lead sponsor
Corewell Health East
Other
Eligibility
2 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Terminated Not applicable Interventional Accepts healthy volunteers

Boosting Primary Care Awareness and Treatment of Childhood Hypertension

NCT03783650
Conditions
Pediatric Hypertension
Interventions
Control condition, QIC with PCP and without subspecialist, QIC with Subspecialist, Hub and Spoke co-management, Sustainability of changes
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Completed Phase 4 Interventional Results available

N-of-1 Trials In Children With Hypertension

NCT03461003
Conditions
Pediatric Hypertension
Interventions
NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 22 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil- Tablet or Oral suspension
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Conditions
Glaucoma, Ocular Hypertension
Interventions
Preservative free tafluprost opthalmic solution
Drug
Lead sponsor
Santen Oy
Industry
Eligibility
1 Month to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hypertension, Blood Pressure
Interventions
Pharmacist Drug Therapy Management
Other
Lead sponsor
University of Louisiana Monroe
Other
Eligibility
4 Years to 20 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Monroe, Louisiana
Completed Phase 3 Interventional Results available

FUTURE 3 Study Extension

NCT01338415
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
3 Months to 12 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New York, New York